Immix Biopharma (IMMX) Profit After Tax (2021 - 2026)

Immix Biopharma has reported Profit After Tax for 6 years, with the latest figure at -$10.1 million in Q1 2026.

• Quarterly Profit After Tax fell 122.86% year-over-year to -$10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.0 million (down 548.31% YoY) and the FY2025 annual result came in at -$29.4 million, down 21561.93% from the prior year.
• Profit After Tax rose to -$10.1 million in Q1 2026 per IMMX's latest filing, from -$10.7 million in the prior quarter.
• Over five years, Profit After Tax peaked at $16.7 million in Q4 2024 and troughed at -$10.7 million in Q4 2025.
• A 5-year average of -$3.3 million and a median of -$4.3 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 434.26% in 2024, then plunged 10203.61% in 2025.
• Over 5 years, Profit After Tax stood at -$3.8 million in 2022, then tumbled by 31.21% to -$5.0 million in 2023, then jumped by 434.26% to $16.7 million in 2024, then slumped by 164.28% to -$10.7 million in 2025, then increased by 5.84% to -$10.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$10.1 million, -$10.7 million, and -$7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.